Glucagon

Generic Name: Glucagon

Brand Names: Baqsimi, Glucagen, Gvoke, Ogluo

Drug Type: Biotech

CAS Number: 16941-32-5

Unique Ingredient Identifier: 76LA80IG2G

Background: Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia. Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and the release of glucose.

Glucagon was granted FDA approval on 14 November 1960.

Indication: Glucagon is indicated as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.

Associated Conditions: Severe Hypoglycemia

Clinical Trials

Assessment of Intranasal Glucagon in Children and Adolescents With Type 1 Diabetes

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Nasal Glucagon
Drug: Intramuscular Glucagon

First Posted Date: 2013-11-28

Last Posted Date: 2018-08-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT01997411

Locations: 🇺🇸
Barbara Davis Center for Diabetes, Aurora, Colorado, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
University of Florida, Gainesville, Florida, United States

and more 4 locations

Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Intramuscular Glucagon
Drug: Nasal Glucagon

First Posted Date: 2013-11-26

Last Posted Date: 2019-09-23

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 77

Registration Number: NCT01994746

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States
🇺🇸
Barbara Davis Center for Diabetes, Aurora, Colorado, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

and more 5 locations

Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Glucagon

First Posted Date: 2013-11-18

Last Posted Date: 2015-05-04

Lead Sponsor: Legacy Health System

Target Recruit Count: 12

Registration Number: NCT01986231

Locations: 🇺🇸
Oregon Health and Science University, Portland, Oregon, United States

Evaluate the Immunogenicity of a Novel Glucagon Formulation

Phase 3

Completed

Conditions: Drug-specific Antibodies
Diabetes Mellitus

Interventions: Drug: Glucagon IM
Drug: Nasal Glucagon (NG)

First Posted Date: 2013-10-10

Last Posted Date: 2019-09-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 75

Registration Number: NCT01959334

Locations: 🇨🇦
Algorithme Pharma Inc., Laval, Quebec, Canada

Trial to Compare the Relative Pharmacodynamic Properties of Different Glucagon Dosages

Phase 1

Completed

Conditions: Diabetes Mellitus Type 1

Interventions: Drug: Glucagon

First Posted Date: 2013-08-05

Last Posted Date: 2014-02-05

Lead Sponsor: Profil Institut für Stoffwechselforschung GmbH

Target Recruit Count: 6

Registration Number: NCT01916265

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, NRW, Germany

Efficacy of Small Subcutaneous Glucagon Dose to Treat Hypoglycemia in Adults With Type 1 Diabetes

Phase 2

Withdrawn

Conditions: Type 1 Diabetes

Interventions: Procedure: Hypoglycaemic hyperinsulinemic clamp
Drug: Glucagon

First Posted Date: 2013-04-10

Last Posted Date: 2013-12-04

Lead Sponsor: Institut de Recherches Cliniques de Montreal

Registration Number: NCT01828125

Locations: 🇨🇦
Institut de recherches cliniques de Montréal, Montreal, Quebec, Canada

Study of Glucagon, Ghrelin and Growth Hormone as Counterregulatory Hormones

Not Applicable

Conditions: Healthy

Interventions: Drug: Saline
Drug: Glucagon
Drug: Placebo
Drug: Atenolol

First Posted Date: 2013-02-20

Last Posted Date: 2013-02-20

Lead Sponsor: University of Virginia

Target Recruit Count: 6

Registration Number: NCT01795235

Locations: 🇺🇸
University of Virginia, Charlottesville, Virginia, United States

Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization

Phase 4

Withdrawn

Conditions: Women With Fertility Disorder

Interventions: Drug: Glucagon
Drug: placebo

First Posted Date: 2012-08-28

Last Posted Date: 2015-07-28

Lead Sponsor: Clinique Ovo

Registration Number: NCT01674283

Locations: 🇨🇦
Clinique Ovo, Montréal, Quebec, Canada

Study of LY2409021 in Participants With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: LY2409021
Drug: Placebo
Drug: Glucagon

First Posted Date: 2012-07-16

Last Posted Date: 2018-10-29

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 20

Registration Number: NCT01640834

Locations: 🇩🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Neuss, Germany

Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure

Phase 1

Terminated

Conditions: Intestinal Failure
Short Bowel Syndrome

Interventions: Drug: Glucagon-Like Peptide 2
Drug: Glucagon like peptide-2

First Posted Date: 2012-04-09

Last Posted Date: 2014-12-23

Lead Sponsor: Alberta Children's Hospital

Target Recruit Count: 13

Registration Number: NCT01573286

Locations: 🇨🇦
Alberta Children's Hospital, Calgary, Alberta, Canada
🇨🇦
British Columbia Children's Hospital, Vancouver, British Columbia, Canada
🇨🇦
Stollery Children's Hospital, Edmonton, Alberta, Canada

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy